Vitro Biopharma, Inc.
VTRO
New York Stock Exchange Arca0.00
USD
- -
- -
Return %
Stock
S&P500
1Y
- -
19.01
3Y
- -
65.48
5Y
- -
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Similar Companies
- Business
- Vitro Biopharma, Inc. is an innovative biotechnology company specializing in the development of cell therapies derived from Wharton’s jelly of the umbilical cord, targeting autoimmune diseases and inflammatory disorders. The company's core products include AlloRx® stem cell therapy, culture-expanded mesenchymal stem cells (MSCs), and related biologics produced under current Good Manufacturing Practices (cGMP) and with ISO 9001, ISO 13485 certifications. Vitro Biopharma’s offerings extend to stem cell activation products and topical cosmetic stem cell serums through acquisitions of Fitore Nutrition and Infinivive MD. The company's product candidates are used in clinical and research applications globally, notably in conditions such as Pitt-Hopkins syndrome, Long COVID, osteoarthritis, multiple sclerosis, COPD, Alzheimer’s, and lupus. Founded in 1986 and headquartered in Golden, Colorado, Vitro Biopharma operates in multiple geographic regions, conducting clinical trials in locations including the Cayman Islands, New Zealand, the Czech Republic, and the Bahamas. The company maintains FDA registrations and has received Investigational New Drug (IND) authorizations from the U.S. FDA to conduct Phase 1/2a clinical trials for treating rare diseases such as Pitt-Hopkins syndrome and Long COVID. Vitro Biopharma emphasizes product safety and regulatory compliance, with over 1,000 treatments performed without severe adverse events reported. Recent major changes include the acquisition of Fitore Nutrition and Infinivive MD, expanding its revenue base and product portfolio in stem cell activation and regenerative medicine. The company recently appointed Thomas Ohrt as Chief Financial Officer and has engaged in strategic multi-million dollar partnerships, including an operating service agreement with a European biomedical group. Vitro Biopharma has also expanded its clinical trial portfolio with regulatory approvals for musculoskeletal condition treatments and is actively working on business expansion through additional capital raising and diversification of product offerings.
IPO Update: Vitro Biopharma Aims For $10 Million U.S. IPO